P. Koskenvesa

发表

Plasma proteomics of biomarkers for inflammation or cancer cannot predict relapse in chronic myeloid leukaemia patients stopping tyrosine kinase inhibitor therapy.

U. Olsson‐Strömberg, S. Mustjoki, J. Richter, 2020, Leukemia research.

Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia

U. Olsson‐Strömberg, S. Mustjoki, T. Brümmendorf, 2017, Journal of Cancer Research and Clinical Oncology.

Low or undetectable numbers of Philadelphia chromosome-positive leukemic stem cells (Ph+CD34+CD38neg) in chronic myeloid leukemia patients in complete cytogenetic remission after tyrosine kinase inhibitor therapy

S. Mustjoki, K. Porkka, T. Lundán, 2010, Leukemia.

The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia

U. Olsson‐Strömberg, J. Hasford, M. Baccarani, 2020, Leukemia.

Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia.

Arnon Nagler, Johan Lanng Nielsen, Karin Olsson, 2011, Blood.

Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients

U. Olsson‐Strömberg, S. Mustjoki, M. Höglund, 2016, Leukemia.

Induction of sustained deep molecular response in a patient with chronic-phase T315I-mutated chronic myeloid leukemia with interferon-α monotherapy

S. Mustjoki, T. Lion, K. Porkka, 2014, Leukemia & lymphoma.

Imatinib and pegylated IFN‐α2b discontinuation in first‐line chronic myeloid leukemia patients following a major molecular response

S. Mustjoki, K. Porkka, A. Kreutzman, 2014, European journal of haematology.

Impact of tailored patient education on adherence of patients with chronic myeloid leukaemia to tyrosine kinase inhibitors: a randomized multicentre intervention study.

T. Söderlund, M. Airaksinen, K. Talvensaari, 2016, Journal of advanced nursing.

Chronic myeloid leukemia patients’ adherence to peroral tyrosine kinase inhibitors compared with adherence as estimated by their physicians

K. Porkka, M. Airaksinen, K. Talvensaari, 2014, Patient preference and adherence.

The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries

M. Baccarani, R. Clark, K. Indrák, 2015, Leukemia.

Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia.

S. Mustjoki, H. Dombret, M. Höglund, 2008, Blood.

Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)

U. Olsson‐Strömberg, S. Mustjoki, M. Höglund, 2014, European journal of haematology.

central nervous system Philadelphia chromosomepositive leukemia Dasatinib crosses the blood-brain barrier and is an efficient therapy for

S. Mustjoki, H. Dombret, M. Höglund, 2009 .

IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia

U. Olsson‐Strömberg, S. Mustjoki, M. Höglund, 2022, The Journal of clinical investigation.

Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis

T. Brümmendorf, G. Rosti, N. Cross, 2015, Journal of Cancer Research and Clinical Oncology.

Copy number alterations define outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia

S. Mustjoki, T. Siitonen, P. Ellonen, 2022, Haematologica.

Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation

S. Mustjoki, M. Kankainen, O. Brück, 2022, Blood Cancer Journal.

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.

Martin C. Müller, U. Olsson‐Strömberg, S. Mustjoki, 2018, The Lancet. Oncology.

Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia

U. Olsson‐Strömberg, S. Mustjoki, M. Höglund, 2016, Leukemia.

Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML

T. Aittokallio, S. Mustjoki, O. Kallioniemi, 2018, Leukemia.

Early Disease Relapse after Tyrosine Kinase Inhibitor Treatment Discontinuation in CML Is Related Both to Low Number and Impaired Function of NK-Cells

Martin C. Müller, U. Olsson‐Strömberg, S. Mustjoki, 2014 .

Disease Relapse After Tyrosine Kinase Inhibitor Treatment Discontinuation in Chronic Myeloid Leukaemia is Related to Both Low Number and Impaired Function of NK Cells

U. Olsson‐Strömberg, S. Mustjoki, S. Lehmann, 2014 .

Long‐term tolerability and efficacy after initial PegIFN‐α addition to dasatinib in CML‐CP: Five‐year follow‐up of the NordCML007 study

U. Olsson‐Strömberg, S. Mustjoki, B. Gjertsen, 2021, European journal of haematology.

Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia.

Mahmoud M. Kamel, S. Mustjoki, K. Porkka, 2020, Blood advances.

Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR—final report from AFTER-SKI

U. Olsson‐Strömberg, S. Deneberg, J. Richter, 2021, Leukemia.

Disease Relapse After TKI Discontinuation In CML Is Related Both To Low Number and Impaired Function Of NK-Cells:Data From Euro-SKI

U. Olsson‐Strömberg, S. Mustjoki, S. Lehmann, 2013 .

RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses

T. Aittokallio, S. Mustjoki, D. Thomson, 2020, Leukemia.

Treatment and outcome of 2904 CML patients from the EUTOS population-based registry

M. Höglund, M. Baccarani, K. Indrák, 2017, Leukemia.

Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line

U. Olsson‐Strömberg, S. Mustjoki, J. Richter, 2019, Oncoimmunology.

Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing

S. Mustjoki, O. Kallioniemi, J. Mpindi, 2015, Blood Cancer Journal.

Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients

U. Olsson‐Strömberg, S. Mustjoki, T. Fioretos, 2013, Leukemia.

Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin

U. Olsson‐Strömberg, J. Hasford, M. Baccarani, 2019, American journal of hematology.

Imatinib Discontinuation Following a Major Molecular Response: Impact of Interferon Alpha and Leukemia Stem Cell Burden (The STOP Study).

S. Mustjoki, K. Porkka, T. Lundán, 2008 .

Safety and Efficacy of Addition of Pegylated Interferon alpha2b to Standard Dose Dasatinib in Newly Diagnosed Chronic Phase CML Patients

S. Mustjoki, H. Vestergaard, M. Höglund, 2015 .